Investing.com - Ocuphire Pharma (NASDAQ: OCUP) reported second quarter EPS of $-0.300, $0.06 worse than the analyst estimate of $-0.240. Revenue for the quarter came in at $1.11M versus the consensus estimate of $2.6M.
Ocuphire Pharma's stock price closed at $1.65. It is down -1.780% in the last 3 months and down -60.220% in the last 12 months.
Ocuphire Pharma saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Ocuphire Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Ocuphire Pharma's Financial Health score is "good performance".
Check out Ocuphire Pharma's recent earnings performance, and Ocuphire Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar